US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Park Hotels & Resorts Inc.

10.00

+0.01000.10%

Post-market: 10.000.00000.00%16:34 EDT

Volume:3.48M

Turnover:34.69M

Market Cap:2.02B

PE:9.90

High:10.03

Open:9.98

Low:9.82

Close:9.99

Loading ...

Overview Company News Filings

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Press Release: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Press Release: Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

CING: April Pre-NDA Meeting

Zacks Small Cap Research

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Agios to Present at Upcoming Investor Conferences

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Bumitama Agri’s H2 profit climbs 13.5% to 1.43 trillion rupiah

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PK/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","market":"US","secType":"STK","nameCN":"Park Hotels & Resorts Inc.","latestPrice":10,"timestamp":1745611200000,"preClose":9.99,"halted":0,"volume":3478911,"hourTrading":{"tag":"盘后","latestPrice":10,"preClose":10,"latestTime":"16:34 EDT","volume":136516,"amount":1365160,"timestamp":1745613291104},"delay":0,"floatShares":197724425,"shares":201864175,"eps":1.01,"marketStatus":"Post-Mkt","change":0.01,"latestTime":"04-25 17:29:51 EDT","open":9.98,"high":10.0253,"low":9.815,"amount":34690298.490867,"amplitude":0.021051,"askPrice":10.04,"askSize":6,"bidPrice":9.87,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":1.01,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745625600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":9.99,"dividendRate":0.14,"preHourTrading":{"tag":"盘前","latestPrice":10.18,"preClose":9.99,"latestTime":"09:25 EDT","volume":291,"amount":2960.915397,"timestamp":1745587526246},"postHourTrading":{"tag":"盘后","latestPrice":10,"preClose":10,"latestTime":"16:34 EDT","volume":136516,"amount":1365160,"timestamp":1745613291104},"volumeRatio":0.835709,"impliedVol":0.5641,"impliedVolPercentile":0.812},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","floatShares":197724425,"roa":"2.35%","roe":"6.14%","lyrEps":1.019323,"volumeRatio":0.835709,"shares":201864175,"dividePrice":1.4,"high":10.0253,"amplitude":0.021051,"preClose":9.99,"low":9.815,"week52Low":8.27,"pbRate":"0.55","psRate":"0.77","week52High":16.78,"institutionHeld":0,"latestPrice":10,"committee":0.988072,"eps":1.01,"divideRate":0.14,"volume":3478911,"delay":0,"ttmEps":1.01,"open":9.98,"prevYearClose":14.07,"prevWeekClose":9.83,"prevMonthClose":10.68,"prevQuarterClose":10.68,"fiveDayClose":9.83,"twentyDayClose":11.15,"sixtyDayClose":13.35,"earningDate":1746374400000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PK\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519558835","title":"TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519558835","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519558835?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:47","pubTimestamp":1741866420,"startTime":"0","endTime":"0","summary":"Clinical trial Safety Review Committee  approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3. No significant safety or dose limiting toxicities reported in Cohorts 1, 2, or 3. Patients currently being evaluated for Cohort 4 eligibility. \"SRC approval to open the fourth cohort and expand enrollment in Cohort 3 is an important advancement for the clinical trial. It will provide an opportunity to obtain additional safety and PK/PD data, inform the dose expansion stage of the clinical trial and may allow us to obtain initial evidence of clinical activity\" commented Sue Duggan, TransCode's Senior Vice President of Operations. Duggan added, \"Enrollment into the study continues based on the cumulative safety data review. Eligible subjects may now be screened and scheduled in Cohort 4 for treatment with the next dose level of TTX-MC138","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-safety-review-114700704.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-safety-review-114700704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","BK4080","BK4231","RNAZ","LU1169590202.USD","BK4181","BK4139","BK4539","LU1169589451.USD","BK4218","PD","PK","LENZ","SRC"],"gpt_icon":0},{"id":"2519887161","title":"Press Release: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887161?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates. -- Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer's Disease ; plans to initiate Phase 2 clinical trial in Q3 2025 --. -- On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 --. WATERTOWN, Mass., March 13, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided updates on recent progress.Final analysis from IGNITE Phase 2 clinical trial planned for second quarter of 2025:. -- The Company plans to report the final analysis from the IGNITE Phase 2. clinical trial, including all patients at 12 months dosed with either 20. iluzanebart in ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","PK","BK4181","BK4588","BK4099","PD","BK4213","BK4604","03160","BK4555","CSF","LU1169589451.USD","BK4139","VIGL","LU1169590202.USD","BK4218","VG","BK4585","BK4023"],"gpt_icon":0},{"id":"2518748696","title":"Press Release: Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748696","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518748696?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:00","pubTimestamp":1741694400,"startTime":"0","endTime":"0","summary":"-- Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to. Board of Directors; two industry veterans joined management team as Ovid. prepares to take OV329 into patient trials and move its first KCC2 direct. -- Topline results from Phase 1 study of OV329 expected in Q3 2025, which. will include biomarkers that measure clinical effect and target. -- OV350, Ovid's first program in its KCC2 direct activator library,Ovid expects its cash runway to support operations and clinical development programs into the second half of 2026, during which time multiple pipeline and regulatory milestones are anticipated. These anticipated milestones include: results for OV329 biomarker and safety data ; initiation of a Phase 2a patient study for OV329 in drug resistant epilepsies ; results from a first-in-human safety and exploratory biomarker study with OV350, our first KCC2 direct activator ; and initiation of human trials for the first oral KCC2 direct activator, OV4071 . In the eve","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4135","BK4181","A","BK4121","BK4588","IE00BN0W2W23.USD","LU1543694498.USD","BK4585","LU2092937221.SGD","BK4567","LU2413666699.HKD","CNS","OVID","LU2041044095.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU1721428933.USD","LENZ","BK4139","LU1165135440.EUR","LU2413666426.HKD","LU0347712357.USD","PK"],"gpt_icon":0},{"id":"2518423852","title":"Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518423852","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518423852?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:07","pubTimestamp":1741604820,"startTime":"0","endTime":"0","summary":"Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039587/0/en/Design-Therapeutics-Highlights-Progress-Across-Lead-GeneTAC-Programs-and-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU1929549753.HKD","BK4023","BK4534","LU1914381329.SGD","PD","LU2756315318.SGD","LU0320765646.SGD","BK4505","BK4097","BK4539","IE00B1XK9C88.USD","BK4504","LU0234572021.USD","PRGS","LU0943347566.SGD","LU0823434740.USD","IE00BKVL7J92.USD","SG9999001440.SGD","BK4585","BK4533","LU1169590202.USD","LU0079474960.USD","LU2756315664.SGD","LU1989772840.SGD","LU1496350171.SGD","DSGN","HD","LU1093756168.USD","LU1778281490.HKD","LU1035775433.USD","LENZ","LU0823411888.USD","FA","IE00BZ1G4Q59.USD","BK4218","LU1551013342.USD","LU0868494708.USD","LU1093756325.SGD","LU1162221912.USD","BK4535","LU0820561818.USD","PK","LU0868494617.USD","LU0820562030.AUD","IE00BWXC8680.SGD","LU1674673691.USD","BK4181","BK4588","LU0942090050.USD"],"gpt_icon":0},{"id":"2518922748","title":"CING: April Pre-NDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2518922748","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518922748?lang=en_us&edition=fundamental","pubTime":"2025-03-10 17:40","pubTimestamp":1741599600,"startTime":"0","endTime":"0","summary":"Since the report of third quarter results, Cingulate, Inc.  has executed a $5 million capital raise, completed its fast-fed study and reported safety results from its Phase III trials. As we move down the home stretch towards the FDA submission, Cingulate has a pre-new drug application  meeting scheduled for early April and anticipates filing its NDA with the agency by mid-2025. We also expect to see further safety data from the consolidated Phase III studies at an upcoming but as yet unidentified scientific conference.The pathway forward for FDA submission includes several parallel efforts which include updating stability data on 2024 batches of CTx-1301, completing the analysis of the fast fed study and attendance at the pre-NDA meeting with the FDA in early April. Notes from the meeting are expected about a month later, which will provide final details required for completing the NDA. NDA submission is expected by mid-2025. We anticipate a 10-to-12-month turnaround time by the agenc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cing-april-pre-nda-meeting-094000188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4218","BK4007","BK4181","CINGW","BK4535","BK4551","BK4023","CMAX","BK4503","CING","PK","API"],"gpt_icon":0},{"id":"2518440883","title":"Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440883","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518440883?lang=en_us&edition=fundamental","pubTime":"2025-03-09 00:00","pubTimestamp":1741449600,"startTime":"0","endTime":"0","summary":"-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata  --. -- Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound patient requests to re-initiate dosing --. -- Bempikibart development program remains on track with open-label extension study to initiate in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 --. WALTHAM, Mass., March 8, 2025 /PRNewswire/ --Q32 Bio Inc.  , a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata  a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/q32-bio-presents-results-signal-160000777.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q32-bio-presents-results-signal-160000777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","QTTB","BK4139","PK","BK4585","AA","AFG","BK4117","BK4181","BK4588","BK4153","BK4218"],"gpt_icon":0},{"id":"2517276438","title":"Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517276438","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517276438?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:30","pubTimestamp":1741354200,"startTime":"0","endTime":"0","summary":"Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimeki","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038935/0/en/Oruka-Therapeutics-Announces-Preclinical-Data-for-ORKA-002-at-the-2025-American-Academy-of-Dermatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","AFG","ORKA","PK","BK4181","BK4218","BK4139","BK4117"],"gpt_icon":0},{"id":"2517480505","title":"InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480505","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480505?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"JENA, Germany, March  07, 2025  (GLOBE NEWSWIRE) -- InflaRxN.V.(Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038913/0/en/InflaRx-Showcases-Vilobelimab-s-Role-in-Immuno-Dermatology-at-the-2025-AAD-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1929549753.HKD","BK4533","BK4558","LU1162221912.USD","BK4181","LU1066051498.USD","BK4581","LU2129689431.USD","LU2552382215.SGD","LU0094547139.USD","LU0689626769.HKD","BK4567","IE00BBT3K403.USD","BK4535","LU1585245621.USD","PD","ARDS","SG9999015341.SGD","IE00BWXC8680.SGD","SG9999014567.USD","PG","LU1066053197.SGD","BNTX","LU0868494617.USD","BK4139","SG9999002224.SGD","BK4534","LU0061475181.USD","LU0234570918.USD","BK4568","IE00BLSP4239.USD","LU1868836591.USD","USA","LU2129689514.USD","LU1169589451.USD","SG9999015358.SGD","IE00B3T34201.USD","LU0234572021.USD","LU1868837300.USD","BK4018","BK4559","LU1868837136.USD","BK4504","SG9999014575.USD","LU1430594728.SGD","SG9999002232.USD","SG9999014542.SGD","PK","LU1868836914.USD","SG9999001440.SGD"],"gpt_icon":0},{"id":"2517978319","title":"Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978319","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978319?lang=en_us&edition=fundamental","pubTime":"2025-03-06 06:52","pubTimestamp":1741215120,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., March  05, 2025  (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare dis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037841/31990/en/Agios-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4-to-Newly-Appointed-Chief-Corporate-Development-Strategy-Officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU2095319765.USD","IE00B3QW5Z07.USD","STRK","BK4218","BK4585","BK4112","BK4595","LU2210149790.SGD","BK4181","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4600","PK","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP",".IXIC","BK4023","BK4596"],"gpt_icon":1},{"id":"2517921134","title":"ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921134","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921134?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:10","pubTimestamp":1741209000,"startTime":"0","endTime":"0","summary":"neffy1 mgis the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March  05, 2025  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceut","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037769/0/en/ARS-Pharmaceuticals-Announces-FDA-Approval-of-neffy-1-mg-epinephrine-nasal-spray-for-Type-I-Allergic-Reactions-Including-Anaphylaxis-in-Pediatric-Patients-Weighing-15-to-30-Kilogra.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1169589451.USD","PD","PK","BK4181","BK4218","LU1169590202.USD"],"gpt_icon":0},{"id":"2517921680","title":"Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921680","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921680?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:05","pubTimestamp":1741208700,"startTime":"0","endTime":"0","summary":"First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor- (FR) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelinAc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037747/0/en/Zymeworks-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PK","BTC","BK4080","BK4218","BK4590","BK4231","ET","SITC","ADC","BK4181","BK4585","BK4581","BK4144","BK4561"],"gpt_icon":0},{"id":"2516679483","title":"Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2516679483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516679483?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:30","pubTimestamp":1741095000,"startTime":"0","endTime":"0","summary":"GLEN ALLEN, Va., March 04, 2025  -- Adial Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024.Successful completion of AD04-103 pharmacokinetics  study of AD04, corroborating bioavailability, dose proportionality, no food effect, and safety profile consistent with the use of Ondansetron.Advancement towards pivotal Phase 3 trial design supportive of ongoing partnership discussions.FDA confirmation of proposed 505 bridging strategy leveraging the results from AD04-103—a relative bioavailability food-effect study—along with in vitro dissolution data demonstrating equivalence between the reference product and the planned commercial formulation of AD04.“In addition to the key highlights mentioned, we strengthened our regulatory strategy by partnering with Boudi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adial-pharmaceuticals-reports-2024-fiscal-133000017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADIL","BK4006","IE00BHPRN162.USD","LU0170899867.USD","BK4218","LU0149725797.USD","LU0267386448.USD","LU0882574139.USD","LU0971096721.USD","LU1363072403.SGD","IE00BZ1G4Q59.USD","CMC","BK4181","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","PK","BK4007"],"gpt_icon":0},{"id":"2516783936","title":"Agios to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2516783936","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516783936?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., March  04, 2025  (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today annou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036341/31990/en/Agios-to-Present-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4218","BK4181"],"gpt_icon":0},{"id":"2516752656","title":"Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516752656","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516752656?lang=en_us&edition=fundamental","pubTime":"2025-03-04 01:16","pubTimestamp":1741022203,"startTime":"0","endTime":"0","summary":"On Monday, Apogee Therapeutics, Inc.  released interim Phase 1 results from its first-in-human trial of APG990.APG990 interim Phase 1 pharmacokinetic  data showed a half-life of approximately 60 days across doses tested.Key data from the 40-healthy subject trial showed:. APG990 demonstrated a potential best-in-class PK profile, including a half-life of approximately 60 days, supporting the potential for every three- and six-month maintenance dosing. The PK profile supports the potential for a single 2 mL co-formulated injection of APG279  administered every three and six months.APG990 was well tolerated across all five cohorts, with doses up to 1,200mg. The most common  treatment-emergent adverse events  were headache.53% of participants observed at least one TEAE.In addition, preclinical studies of the combination of APG777 and APG990 showed potential for enhanced pharmacologic responses relative to individual agents and exhibited no safety findings at any dose level, including the hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-investigational-atopic-dermatitis-171643556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","LU2106854487.HKD","REGN","LU0889565916.HKD","USAW.SI","LU0109394709.USD","LU0320765992.SGD","IE00BFXG1179.USD","PK","LU0114720955.EUR","QLD","LU2468319806.SGD","LU0058720904.USD","TQQQ","LU2023250504.SGD","LU0289739699.SGD","LU2089984988.USD","LU2362541273.HKD","BK4139","LU2362541513.USD","PSQ","NVIW.SI","BK4218","LU0053666078.USD","LU0882574055.USD","SNY","TSYW.SI","LU1917777945.USD","APGE","QID","BK4585","USJW.SI","LU1974910355.USD","NQmain","BK4007","LU2237438978.USD","SQQQ","LU2362540622.SGD","BK4588","LU0823416689.USD","MNQmain",".IXIC"],"gpt_icon":1},{"id":"2516635992","title":"Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635992","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635992?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat  to other anti-CDI antibiotics in a germ-free mouse model. Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin -or metronidazole -treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity. Notable differences were observed between the microbiome of IBZ- and fidaxomicin -treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studies. Results establish IBZ differentiating effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics like VAN and MET and a narrower spectrum of microbiome alteration compared to FDX. Preparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDI. IBZ has previously been granted FDA QIDP a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-announces-publication-nonclinical-vivo-130000861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0251131958.USD","NCI","BK4202","VRE","LU1267930227.SGD","MAA","LU0742534661.SGD","LU1989772840.SGD","MET","BK4215","GAIN","LU1496350502.SGD","LU0251142724.SGD","PK","BK4588","LU1989772923.USD","BK4131","FDX","LU0048573561.USD","BK4135","BK4585","LU0128525689.USD","BK4563","LU1989771016.USD","BK4181","BK4218","BK4139","LU0310800965.SGD","LU1571399168.USD","BK4162","ECC","BK4539","LU1291159041.SGD","LU0052756011.USD","BK4533","BK4194","ACXP","IDSA"],"gpt_icon":0},{"id":"2516877576","title":"Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2516877576","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516877576?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - - MAD study initiated in patients wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035441/36461/en/Voyager-Reports-Positive-Topline-Data-for-Single-Ascending-Dose-SAD-Trial-of-Anti-Tau-Antibody-VY7523-and-Initiates-Multiple-Ascending-Dose-MAD-Trial-in-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","CSF","PET","BK4218","BK4192","PK"],"gpt_icon":0},{"id":"2516684183","title":"Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684183","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684183?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:05","pubTimestamp":1740999900,"startTime":"0","endTime":"0","summary":"Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035381/0/en/Apogee-Therapeutics-Provides-Pipeline-Progress-and-Reports-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4181","BK4139","PRGS","BK4218","APGE","LU1169589451.USD","LU1169590202.USD","BK4097","BK4023","LU2065732104.USD","TSLP","PD"],"gpt_icon":0},{"id":"2514221683","title":"Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514221683","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514221683?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"-- Updated data show AYVAKIT  was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy --. -- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course --. -- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor --. AYVAKIT: PIONEER Three-Year Efficacy and Safety Data in ISM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/blueprint-medicines-highlights-leading-portfolio-130000418.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blueprint-medicines-highlights-leading-portfolio-130000418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BPMC","BK4563","QD","BK4213","SM","BK4188","BK4166","BK4181","BK4503","BK4505","ASM","BK4139","LU0053671581.USD","BK4218","PK","BK4185","JYNT"],"gpt_icon":0},{"id":"2514358922","title":"Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2514358922","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514358922?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:15","pubTimestamp":1740690900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025  -- Alumis Inc.  , a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the Company will give two data presentations on A-005, a potent, selective, central nervous system  penetrant tyrosine kinase 2  inhibitor, on Friday, February 28, 2025, at the 10th Annual Americas Committee for Treatment and Research in Multiple Sclerosis  Forum 2025.“These data demonstrate that A-005 potently inhibits TYK2-specific signaling in immune cells and CNS resident cells, targeting pro-inflammatory cytokine pathways implicated in the pathology of neuroinflammatory diseases,” said Jrn Drappa, M.D., Alumis’ Chief Medical Officer. “As the first reported allosteric TYK2 inhibitor with demonstrated ability to cross the blood-brain barrier, A-005 represents a novel approach to potentially treating a bro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-presents-additional-phase-1-211500176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4179","FET","PD","BK4135","BK4181","LU1169590202.USD","BK4218","ALMS","BK4007","BK4023","CNS","LU1169589451.USD"],"gpt_icon":0},{"id":"2514813421","title":"Bumitama Agri’s H2 profit climbs 13.5% to 1.43 trillion rupiah","url":"https://stock-news.laohu8.com/highlight/detail?id=2514813421","media":"businesstimes","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514813421?lang=en_us&edition=fundamental","pubTime":"2025-02-27 01:01","pubTimestamp":1740589307,"startTime":"0","endTime":"0","summary":"This translates to earnings per share of 825 rupiah for H2 2024, up from 727 rupiah in the year-ago period ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/companies-markets/bumitama-agris-h2-profit-climbs-13-5-1-43-trillion-rupiah","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/companies-markets/bumitama-agris-h2-profit-climbs-13-5-1-43-trillion-rupiah","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["BK4181","PK","BK4218"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PK\",params:#limit:5,,,undefined,":[{"date":"2025-05-05","symbol":"PK","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.39,"defaultRemindTime":1746432000000,"name":null,"time":"Pre-Market","dateTimestamp":1746417600000,"actualEps":null},{"date":"2025-03-31","symbol":"PK","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-15","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-15"},{"date":"2025-02-19","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":0.37,"defaultRemindTime":1739998800000,"name":null,"time":"Post Market","dateTimestamp":1739941200000,"actualEps":null},{"date":"2024-12-31","symbol":"PK","amount":0.65,"announcedDate":"2024-11-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-31","defaultRemindTime":1735655400000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-15","payableDate":"2024-12-31","currency":"USD","dateTimestamp":1735621200000,"payDate":"2025-01-15"},{"date":"2024-10-29","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/09","expectedEps":0.47,"defaultRemindTime":1730232000000,"name":null,"time":"Post Market","dateTimestamp":1730174400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PK\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-17","value":0.43,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-17","value":0.43,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-16","value":0.43,"currency":"USD"},{"executeDate":"2017-12-28","recordDate":"2017-12-29","paymentDate":"2018-01-16","value":0.55,"currency":"USD"},{"executeDate":"2018-03-28","recordDate":"2018-03-30","paymentDate":"2018-04-16","value":0.43,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PK\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.25,"hold":0.625,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":16,"updateTime":1744257600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PK\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PK","date":"2025-04-24","current":9.417154,"percent":0.686935,"low":-68.24471,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"high":55.399897,"avg":-2.80083,"sd":27.197354,"marketCap":1996436690},"quantilePoints":[{"date":"2020-05-01","current":6.781686,"twenty":11.855583,"median":14.661134,"eighty":31.814372,"marketCap":2075195859},{"date":"2020-05-08","current":6.844479,"twenty":11.80177,"median":14.646936,"eighty":31.785807,"marketCap":2094410636},{"date":"2020-05-15","current":-3.602916,"twenty":11.684678,"median":14.629627,"eighty":31.749191,"marketCap":1722193974},{"date":"2020-05-22","current":-4.628096,"twenty":11.308585,"median":14.609077,"eighty":31.647673,"marketCap":2212230016},{"date":"2020-05-29","current":-4.844961,"twenty":11.239782,"median":14.592668,"eighty":31.498937,"marketCap":2315891487},{"date":"2020-06-05","current":-6.446805,"twenty":11.167874,"median":14.571217,"eighty":31.464863,"marketCap":3081572803},{"date":"2020-06-12","current":-5.712421,"twenty":11.131908,"median":14.542822,"eighty":31.43819,"marketCap":2730537369},{"date":"2020-06-19","current":-5.278691,"twenty":11.055905,"median":14.514879,"eighty":31.414917,"marketCap":2523214428},{"date":"2020-06-26","current":-4.682313,"twenty":10.886453,"median":14.495498,"eighty":31.375334,"marketCap":2238145384},{"date":"2020-07-02","current":-4.746386,"twenty":10.800505,"median":14.4813,"eighty":31.352562,"marketCap":2268772637},{"date":"2020-07-10","current":-4.756244,"twenty":10.682725,"median":14.429243,"eighty":31.344509,"marketCap":2273484522},{"date":"2020-07-17","current":-4.514735,"twenty":7.464564,"median":14.377186,"eighty":31.340758,"marketCap":2158043339},{"date":"2020-07-24","current":-4.204224,"twenty":6.899423,"median":14.324128,"eighty":31.317149,"marketCap":2009618961},{"date":"2020-07-31","current":-4.076076,"twenty":6.656099,"median":14.175607,"eighty":31.295818,"marketCap":1948364455},{"date":"2020-08-07","current":-2.566048,"twenty":6.428473,"median":14.137595,"eighty":31.259301,"marketCap":2101593620},{"date":"2020-08-14","current":-2.721392,"twenty":6.26364,"median":14.089266,"eighty":31.247128,"marketCap":2228820140},{"date":"2020-08-21","current":-2.525774,"twenty":6.153752,"median":14.006744,"eighty":31.247128,"marketCap":2068608967},{"date":"2020-08-28","current":-2.870982,"twenty":5.863333,"median":13.870814,"eighty":31.210909,"marketCap":2351334566},{"date":"2020-09-04","current":-3.046463,"twenty":5.667103,"median":13.801033,"eighty":31.128278,"marketCap":2495053412},{"date":"2020-09-11","current":-2.902626,"twenty":5.384533,"median":13.774657,"eighty":31.118835,"marketCap":2377251079},{"date":"2020-09-18","current":-3.095368,"twenty":4.792705,"median":13.714879,"eighty":31.059812,"marketCap":2535106206},{"date":"2020-09-25","current":-2.819201,"twenty":2.477694,"median":13.678818,"eighty":30.998429,"marketCap":2308925726},{"date":"2020-10-02","current":-3.046463,"twenty":2.452731,"median":13.647472,"eighty":30.967738,"marketCap":2495053412},{"date":"2020-10-09","current":-3.103998,"twenty":2.419945,"median":13.625211,"eighty":30.925242,"marketCap":2542174346},{"date":"2020-10-16","current":-2.865229,"twenty":2.407631,"median":13.604071,"eighty":30.830806,"marketCap":2346622473},{"date":"2020-10-23","current":-3.106875,"twenty":2.39881,"median":13.60157,"eighty":30.809558,"marketCap":2544530392},{"date":"2020-10-30","current":-2.856599,"twenty":2.384831,"median":13.570144,"eighty":30.743453,"marketCap":2339554333},{"date":"2020-11-06","current":-2.206192,"twenty":2.293797,"median":13.511461,"eighty":30.717484,"marketCap":2426811706},{"date":"2020-11-13","current":-3.043689,"twenty":2.260846,"median":13.488575,"eighty":30.70568,"marketCap":3348057703},{"date":"2020-11-20","current":-3.221469,"twenty":2.22504,"median":13.471041,"eighty":30.674988,"marketCap":3543616316},{"date":"2020-11-27","current":-3.581314,"twenty":2.209754,"median":13.450169,"eighty":30.667905,"marketCap":3939445798},{"date":"2020-12-04","current":-3.885469,"twenty":2.206595,"median":13.437336,"eighty":30.660823,"marketCap":4274015956},{"date":"2020-12-11","current":-3.77623,"twenty":2.197164,"median":13.4098,"eighty":30.634853,"marketCap":4153853434},{"date":"2020-12-18","current":-3.649856,"twenty":2.188516,"median":13.398907,"eighty":30.606523,"marketCap":4014841890},{"date":"2020-12-24","current":-3.681985,"twenty":2.181468,"median":13.390367,"eighty":30.587635,"marketCap":4050183808},{"date":"2020-12-31","current":-3.673418,"twenty":2.165633,"median":13.373288,"eighty":30.559305,"marketCap":4040759297},{"date":"2021-01-08","current":-3.726966,"twenty":2.127386,"median":13.357167,"eighty":30.487456,"marketCap":4099662493},{"date":"2021-01-15","current":-3.711972,"twenty":2.090996,"median":13.34366,"eighty":30.406499,"marketCap":4083169598},{"date":"2021-01-22","current":-3.889753,"twenty":2.071846,"median":13.334859,"eighty":30.325661,"marketCap":4278728211},{"date":"2021-01-29","current":-3.572747,"twenty":2.068781,"median":13.320798,"eighty":30.089882,"marketCap":3930021287},{"date":"2021-02-05","current":-3.887611,"twenty":2.05882,"median":13.314589,"eighty":29.899013,"marketCap":4276372084},{"date":"2021-02-12","current":-4.215327,"twenty":2.034301,"median":13.288201,"eighty":29.854103,"marketCap":4636859648},{"date":"2021-02-19","current":-4.444514,"twenty":2.013845,"median":13.280132,"eighty":29.737337,"marketCap":4888965330},{"date":"2021-02-26","current":-3.563311,"twenty":-2.231897,"median":13.271323,"eighty":29.699163,"marketCap":5131167540},{"date":"2021-03-05","current":-3.448497,"twenty":-2.455006,"median":13.256856,"eighty":29.625061,"marketCap":4965836198},{"date":"2021-03-12","current":-3.740659,"twenty":-2.561446,"median":13.245191,"eighty":29.508294,"marketCap":5386549593},{"date":"2021-03-19","current":-3.755425,"twenty":-2.654652,"median":13.226158,"eighty":29.474611,"marketCap":5407812650},{"date":"2021-03-26","current":-3.589648,"twenty":-2.723118,"median":13.200933,"eighty":29.409492,"marketCap":5169093647},{"date":"2021-04-01","current":-3.581442,"twenty":-2.747858,"median":13.188305,"eighty":29.387036,"marketCap":5157275875},{"date":"2021-04-09","current":-3.522353,"twenty":-2.785256,"median":13.150762,"eighty":29.281497,"marketCap":5072187914},{"date":"2021-04-16","current":-3.497732,"twenty":-2.84164,"median":13.078426,"eighty":29.200659,"marketCap":5036734596},{"date":"2021-04-23","current":-3.597855,"twenty":-2.856599,"median":13.071715,"eighty":29.043473,"marketCap":5180911420},{"date":"2021-04-30","current":-3.661868,"twenty":-2.86063,"median":13.065856,"eighty":28.92446,"marketCap":5273090044},{"date":"2021-05-07","current":-5.611001,"twenty":-2.872133,"median":13.00038,"eighty":27.600316,"marketCap":5285562943},{"date":"2021-05-14","current":-5.538196,"twenty":-2.918736,"median":12.98625,"eighty":26.702293,"marketCap":5216980694},{"date":"2021-05-21","current":-5.07124,"twenty":-2.973394,"median":12.984113,"eighty":26.504319,"marketCap":4777108342},{"date":"2021-05-28","current":-5.219361,"twenty":-3.010216,"median":12.953043,"eighty":26.370989,"marketCap":4916637744},{"date":"2021-06-04","current":-5.151577,"twenty":-3.032655,"median":12.935438,"eighty":26.342707,"marketCap":4852785306},{"date":"2021-06-11","current":-5.407649,"twenty":-3.066646,"median":12.921003,"eighty":26.23968,"marketCap":5094005628},{"date":"2021-06-18","current":-5.181703,"twenty":-3.103007,"median":12.910479,"eighty":26.122512,"marketCap":4881164167},{"date":"2021-06-25","current":-5.407649,"twenty":-3.130464,"median":12.883118,"eighty":26.110391,"marketCap":5094005628},{"date":"2021-07-02","current":-5.103877,"twenty":-3.201231,"median":12.837305,"eighty":26.041706,"marketCap":4807852108},{"date":"2021-07-09","current":-4.933162,"twenty":-3.220989,"median":12.808486,"eighty":25.863933,"marketCap":4647038560},{"date":"2021-07-16","current":-4.616837,"twenty":-3.39668,"median":12.795175,"eighty":25.55283,"marketCap":4349060515},{"date":"2021-07-23","current":-4.684621,"twenty":-3.442298,"median":12.778454,"eighty":25.461924,"marketCap":4412912953},{"date":"2021-07-30","current":-4.644453,"twenty":-3.472857,"median":12.762007,"eighty":25.27203,"marketCap":4375074472},{"date":"2021-08-06","current":-5.555659,"twenty":-3.499046,"median":12.754728,"eighty":25.175063,"marketCap":4438971639},{"date":"2021-08-13","current":-5.472783,"twenty":-3.515459,"median":12.739067,"eighty":25.092237,"marketCap":4372753628},{"date":"2021-08-20","current":-5.209355,"twenty":-3.540249,"median":12.712634,"eighty":25.013451,"marketCap":4162274952},{"date":"2021-08-27","current":-5.74509,"twenty":-3.546559,"median":12.705805,"eighty":24.987189,"marketCap":4590327091},{"date":"2021-09-03","current":-5.52902,"twenty":-3.565932,"median":12.702277,"eighty":24.944766,"marketCap":4417687278},{"date":"2021-09-10","current":-5.437265,"twenty":-3.571599,"median":12.695796,"eighty":24.807396,"marketCap":4344374481},{"date":"2021-09-17","current":-5.688853,"twenty":-3.581314,"median":12.675381,"eighty":24.746792,"marketCap":4545393441},{"date":"2021-09-24","current":-5.97004,"twenty":-3.589648,"median":12.636863,"eighty":24.72659,"marketCap":4770061692},{"date":"2021-10-01","current":-5.896043,"twenty":-3.599497,"median":12.622139,"eighty":24.665986,"marketCap":4710938468},{"date":"2021-10-08","current":-5.721411,"twenty":-3.607845,"median":12.595518,"eighty":24.655885,"marketCap":4571407660},{"date":"2021-10-15","current":-5.659254,"twenty":-3.625758,"median":12.578404,"eighty":24.655885,"marketCap":4521744152},{"date":"2021-10-22","current":-5.505341,"twenty":-3.649856,"median":12.569511,"eighty":24.645785,"marketCap":4398767847},{"date":"2021-10-29","current":-5.484622,"twenty":-3.670075,"median":12.545167,"eighty":24.625583,"marketCap":4382213344},{"date":"2021-11-05","current":-8.201051,"twenty":-3.681985,"median":12.518997,"eighty":24.605382,"marketCap":4994440260},{"date":"2021-11-12","current":-7.56811,"twenty":-3.701263,"median":12.505104,"eighty":24.575079,"marketCap":4608979198},{"date":"2021-11-19","current":-7.339009,"twenty":-3.720957,"median":12.481428,"eighty":24.44377,"marketCap":4469456483},{"date":"2021-11-26","current":-6.989532,"twenty":-3.729965,"median":12.465978,"eighty":24.427609,"marketCap":4256625222},{"date":"2021-12-03","current":-6.488616,"twenty":-3.750955,"median":12.411262,"eighty":24.415488,"marketCap":3951567081},{"date":"2021-12-10","current":-7.129323,"twenty":-3.770233,"median":12.390156,"eighty":24.397368,"marketCap":4341757726},{"date":"2021-12-17","current":-6.752665,"twenty":-3.792938,"median":12.369502,"eighty":24.247831,"marketCap":4112372922},{"date":"2021-12-23","current":-7.490449,"twenty":-3.83227,"median":12.348324,"eighty":24.162969,"marketCap":4561683362},{"date":"2021-12-31","current":-7.331243,"twenty":-3.873903,"median":12.336915,"eighty":24.124587,"marketCap":4464726899},{"date":"2022-01-07","current":-7.692369,"twenty":-3.888468,"median":12.314228,"eighty":24.072063,"marketCap":4684652535},{"date":"2022-01-14","current":-7.548695,"twenty":-3.917478,"median":12.283673,"eighty":24.03368,"marketCap":4597155239},{"date":"2022-01-21","current":-7.032246,"twenty":-3.996222,"median":12.241172,"eighty":24.02964,"marketCap":4282637931},{"date":"2022-01-28","current":-6.803145,"twenty":-4.087905,"median":12.214275,"eighty":24.013479,"marketCap":4143115216},{"date":"2022-02-04","current":-7.051662,"twenty":-4.210886,"median":12.177189,"eighty":23.964995,"marketCap":4294461890},{"date":"2022-02-11","current":-7.339009,"twenty":-4.305038,"median":12.115818,"eighty":23.924593,"marketCap":4469456483},{"date":"2022-02-18","current":-9.97933,"twenty":-4.379327,"median":12.077002,"eighty":23.906411,"marketCap":4580512556},{"date":"2022-02-25","current":-9.762948,"twenty":-4.434604,"median":12.034907,"eighty":23.88419,"marketCap":4481193234},{"date":"2022-03-04","current":-9.294121,"twenty":-4.477502,"median":11.989722,"eighty":23.857928,"marketCap":4266001369},{"date":"2022-03-11","current":-9.515655,"twenty":-4.530065,"median":11.874947,"eighty":23.585208,"marketCap":4367685437},{"date":"2022-03-18","current":-9.793479,"twenty":-4.62021,"median":11.802039,"eighty":23.304408,"marketCap":4495206674},{"date":"2022-03-25","current":-9.839796,"twenty":-4.668569,"median":11.613959,"eighty":23.136735,"marketCap":4516466191},{"date":"2022-04-01","current":-10.045649,"twenty":-4.723283,"median":11.244693,"eighty":22.801391,"marketCap":4610952931},{"date":"2022-04-08","current":-8.795089,"twenty":-4.748358,"median":11.177001,"eighty":22.577155,"marketCap":4036945983},{"date":"2022-04-14","current":-9.860381,"twenty":-4.774334,"median":11.132722,"eighty":22.280194,"marketCap":4525914865},{"date":"2022-04-22","current":-9.999332,"twenty":-4.831692,"median":11.002063,"eighty":21.938028,"marketCap":4589693414},{"date":"2022-04-29","current":-10.143429,"twenty":-4.933265,"median":10.846102,"eighty":20.988446,"marketCap":4655834133},{"date":"2022-05-06","current":-13.808923,"twenty":-5.010567,"median":10.72108,"eighty":20.329014,"marketCap":4501708843},{"date":"2022-05-13","current":-13.178967,"twenty":-5.093895,"median":7.386072,"eighty":20.146479,"marketCap":4296343172},{"date":"2022-05-20","current":-11.861786,"twenty":-5.147058,"median":6.828781,"eighty":19.994366,"marketCap":3866942225},{"date":"2022-05-27","current":-13.143174,"twenty":-5.175677,"median":6.45202,"eighty":19.781409,"marketCap":4284674668},{"date":"2022-06-03","current":-13.207601,"twenty":-5.20439,"median":6.373529,"eighty":19.661408,"marketCap":4305677976},{"date":"2022-06-10","current":-12.055068,"twenty":-5.217352,"median":6.1773,"eighty":18.57907,"marketCap":3929952147},{"date":"2022-06-17","current":-10.229627,"twenty":-5.287145,"median":5.839785,"eighty":18.013987,"marketCap":3334858443},{"date":"2022-06-24","current":-10.1652,"twenty":-5.323251,"median":5.651405,"eighty":17.603643,"marketCap":3313855136},{"date":"2022-07-01","current":-9.70705,"twenty":-5.360954,"median":5.101963,"eighty":17.208917,"marketCap":3164498284},{"date":"2022-07-08","current":-9.85738,"twenty":-5.388567,"median":3.861793,"eighty":17.068349,"marketCap":3213506001},{"date":"2022-07-15","current":-9.921808,"twenty":-5.409668,"median":2.45556,"eighty":16.809931,"marketCap":3234509308},{"date":"2022-07-22","current":-10.487336,"twenty":-5.439477,"median":2.417283,"eighty":16.594109,"marketCap":3418871672},{"date":"2022-07-29","current":-11.160244,"twenty":-5.472783,"median":2.404801,"eighty":15.354106,"marketCap":3638239547},{"date":"2022-08-05","current":-56.398031,"twenty":-5.505341,"median":2.387327,"eighty":15.148576,"marketCap":3383881882},{"date":"2022-08-12","current":-60.145409,"twenty":-5.52902,"median":2.299955,"eighty":15.006602,"marketCap":3608724532},{"date":"2022-08-19","current":-55.873399,"twenty":-5.552107,"median":2.257518,"eighty":14.887345,"marketCap":3352403911},{"date":"2022-08-26","current":-53.287708,"twenty":-5.563474,"median":2.212781,"eighty":14.845845,"marketCap":3197262483},{"date":"2022-09-02","current":-52.238442,"twenty":-5.614856,"median":2.207821,"eighty":14.818112,"marketCap":3134306541},{"date":"2022-09-09","current":-54.786659,"twenty":-5.644455,"median":2.197209,"eighty":14.800268,"marketCap":3287199543},{"date":"2022-09-16","current":-52.051073,"twenty":-5.663398,"median":2.187137,"eighty":14.752289,"marketCap":3123064408},{"date":"2022-09-23","current":-44.593792,"twenty":-5.688853,"median":2.168482,"eighty":14.705619,"marketCap":2675627535},{"date":"2022-09-30","current":-42.195471,"twenty":-5.714833,"median":2.125089,"eighty":14.651669,"marketCap":2531728239},{"date":"2022-10-07","current":-43.582,"twenty":-5.729107,"median":2.082185,"eighty":14.616649,"marketCap":2614920019},{"date":"2022-10-14","current":-44.219054,"twenty":-5.777649,"median":2.070313,"eighty":14.587307,"marketCap":2653143270},{"date":"2022-10-21","current":-47.216957,"twenty":-5.925642,"median":2.05882,"eighty":14.530184,"marketCap":2833017390},{"date":"2022-10-28","current":-48.828329,"twenty":-6.246611,"median":2.029326,"eighty":14.486979,"marketCap":2929699729},{"date":"2022-11-04","current":43.862859,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2675634425},{"date":"2022-11-11","current":47.03278,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2868999602},{"date":"2022-11-18","current":45.005505,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2745335826},{"date":"2022-11-25","current":45.742696,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2790304471},{"date":"2022-12-02","current":46.553606,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2839769982},{"date":"2022-12-09","current":45.41096,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2770068581},{"date":"2022-12-16","current":44.342034,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2704864044},{"date":"2022-12-23","current":42.941371,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2619423617},{"date":"2022-12-30","current":43.457404,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2650901669},{"date":"2023-01-06","current":44.010298,"twenty":-6.452657,"median":2.015912,"eighty":14.499284,"marketCap":2684628154},{"date":"2023-01-13","current":46.332449,"twenty":-6.452657,"median":2.015912,"eighty":14.544715,"marketCap":2826279388},{"date":"2023-01-20","current":47.585674,"twenty":-6.452657,"median":2.015912,"eighty":14.591155,"marketCap":2902726086},{"date":"2023-01-27","current":53.188324,"twenty":-6.452657,"median":2.015912,"eighty":14.629303,"marketCap":3244487794},{"date":"2023-02-03","current":54.478409,"twenty":-6.452657,"median":2.015912,"eighty":14.659241,"marketCap":3323182924},{"date":"2023-02-10","current":52.598572,"twenty":-6.452657,"median":2.015912,"eighty":14.710351,"marketCap":3208512877},{"date":"2023-02-17","current":50.681875,"twenty":-6.452657,"median":2.015912,"eighty":14.776825,"marketCap":3091594398},{"date":"2023-02-24","current":19.081678,"twenty":-6.452657,"median":2.015912,"eighty":14.800268,"marketCap":3091231855},{"date":"2023-03-03","current":19.2873,"twenty":-6.452657,"median":2.020509,"eighty":14.820409,"marketCap":3124542543},{"date":"2023-03-10","current":17.080295,"twenty":-6.452657,"median":2.020509,"eighty":14.858004,"marketCap":2767007824},{"date":"2023-03-17","current":15.80726,"twenty":-6.452657,"median":2.020509,"eighty":14.898703,"marketCap":2560776060},{"date":"2023-03-24","current":15.423721,"twenty":-6.452657,"median":2.034301,"eighty":15.020423,"marketCap":2498642845},{"date":"2023-03-31","current":16.930479,"twenty":-6.449731,"median":2.061884,"eighty":15.148576,"marketCap":2742737617},{"date":"2023-04-06","current":16.355172,"twenty":-6.449731,"median":2.08027,"eighty":15.339767,"marketCap":2649537795},{"date":"2023-04-14","current":16.231891,"twenty":-6.452657,"median":2.187137,"eighty":15.656584,"marketCap":2629566405},{"date":"2023-04-21","current":16.1771,"twenty":-6.452657,"median":2.20399,"eighty":16.160663,"marketCap":2620690231},{"date":"2023-04-28","current":15.916842,"twenty":-6.452657,"median":3.861793,"eighty":16.193538,"marketCap":2578528407},{"date":"2023-05-05","current":10.781494,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2716936387},{"date":"2023-05-12","current":11.431806,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2880815089},{"date":"2023-05-19","current":11.705622,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2949816648},{"date":"2023-05-26","current":11.13232,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2805344634},{"date":"2023-06-02","current":11.115206,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2801032037},{"date":"2023-06-09","current":12.184799,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":3070569377},{"date":"2023-06-16","current":11.243558,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2833376518},{"date":"2023-06-23","current":10.71304,"twenty":-6.455582,"median":4.787996,"eighty":16.201756,"marketCap":2699685997},{"date":"2023-06-30","current":10.926958,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2753593465},{"date":"2023-07-07","current":11.226444,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2829063920},{"date":"2023-07-14","current":11.799746,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2973535934},{"date":"2023-07-21","current":11.260671,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2837689115},{"date":"2023-07-28","current":10.76438,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2712623789},{"date":"2023-08-04","current":-57.485197,"twenty":-6.501042,"median":3.861793,"eighty":16.209975,"marketCap":2759289480},{"date":"2023-08-11","current":-60.090736,"twenty":-6.750335,"median":-2.450979,"eighty":16.209975,"marketCap":2884355344},{"date":"2023-08-18","current":-56.854736,"twenty":-6.930509,"median":-2.566048,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-25","current":-56.854736,"twenty":-7.00324,"median":-2.678241,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-31","current":-58.203069,"twenty":-7.047778,"median":-2.730022,"eighty":16.209975,"marketCap":2793747322},{"date":"2023-09-08","current":-56.225513,"twenty":-7.135536,"median":-2.76742,"eighty":16.220933,"marketCap":2698824633},{"date":"2023-09-13","current":-59.641292,"twenty":-7.238826,"median":-2.81236,"eighty":16.220933,"marketCap":2862782005},{"date":"2023-09-20","current":-56.49518,"twenty":-7.292412,"median":-2.856599,"eighty":16.226412,"marketCap":2711768636},{"date":"2023-09-29","current":-56.270458,"twenty":-7.33179,"median":-2.859478,"eighty":16.256547,"marketCap":2700981967},{"date":"2023-10-06","current":-54.068179,"twenty":-7.350658,"median":-2.872421,"eighty":16.256547,"marketCap":2595272609},{"date":"2023-10-13","current":-54.023235,"twenty":-7.41434,"median":-2.928517,"eighty":16.256547,"marketCap":2593115275},{"date":"2023-10-20","current":-52.944568,"twenty":-7.474917,"median":-3.004751,"eighty":16.256547,"marketCap":2541339263},{"date":"2023-10-23","current":-52.405235,"twenty":-7.491226,"median":-3.007627,"eighty":16.256547,"marketCap":2515451257},{"date":"2023-11-03","current":-48.333767,"twenty":-7.537046,"median":-3.046463,"eighty":16.355172,"marketCap":2706690937},{"date":"2023-11-10","current":-48.821216,"twenty":-7.614707,"median":-3.102759,"eighty":16.355172,"marketCap":2733988086},{"date":"2023-11-17","current":-52.758411,"twenty":-7.692369,"median":-3.147149,"eighty":16.355172,"marketCap":2954470996},{"date":"2023-11-24","current":-54.558271,"twenty":-8.07291,"median":-3.21274,"eighty":16.355172,"marketCap":3055263184},{"date":"2023-12-01","current":-55.60819,"twenty":-8.887723,"median":-3.353198,"eighty":16.355172,"marketCap":3114058626},{"date":"2023-12-08","current":-56.170646,"twenty":-9.20165,"median":-3.416563,"eighty":16.355172,"marketCap":3145556185},{"date":"2023-12-13","current":-57.820518,"twenty":-9.294121,"median":-3.460856,"eighty":16.355172,"marketCap":3237949024},{"date":"2023-12-22","current":-62.432661,"twenty":-9.507389,"median":-3.497732,"eighty":16.36339,"marketCap":3496229004},{"date":"2024-01-05","current":-59.020425,"twenty":-9.574387,"median":-3.519891,"eighty":16.393525,"marketCap":3305143815},{"date":"2024-01-12","current":-60.445315,"twenty":-9.664756,"median":-3.542049,"eighty":16.393525,"marketCap":3384937630},{"date":"2024-01-19","current":-59.99535,"twenty":-9.712777,"median":-3.553469,"eighty":16.401744,"marketCap":3359739584},{"date":"2024-01-26","current":-58.232986,"twenty":-9.763771,"median":-3.571596,"eighty":16.393525,"marketCap":3261047233},{"date":"2024-02-02","current":-66.888565,"twenty":-9.823019,"median":-3.581378,"eighty":16.393525,"marketCap":3210651139},{"date":"2024-02-09","current":-57.220565,"twenty":-9.869644,"median":-3.59147,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-16","current":-57.220565,"twenty":-9.956321,"median":-3.604489,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-23","current":-60.89528,"twenty":-10.043591,"median":-3.622011,"eighty":16.393525,"marketCap":3410135677},{"date":"2024-03-01","current":35.936019,"twenty":-10.056469,"median":-3.625758,"eighty":16.447807,"marketCap":3485793844},{"date":"2024-03-08","current":37.18843,"twenty":-10.056469,"median":-3.625758,"eighty":16.567212,"marketCap":3607277745},{"date":"2024-03-15","current":36.961243,"twenty":-10.056469,"median":-3.625758,"eighty":16.670221,"marketCap":3585240545},{"date":"2024-03-22","current":38.523902,"twenty":-10.056469,"median":-3.625758,"eighty":16.766106,"marketCap":3736818537},{"date":"2024-03-28","current":38.306866,"twenty":-10.056469,"median":-3.625758,"eighty":16.809931,"marketCap":3715766038},{"date":"2024-04-05","current":37.156575,"twenty":-10.059306,"median":-3.629041,"eighty":16.978896,"marketCap":3604187794},{"date":"2024-04-12","current":37.894498,"twenty":-10.059306,"median":-3.629041,"eighty":17.16064,"marketCap":3675766290},{"date":"2024-04-19","current":35.007918,"twenty":-10.059306,"median":-3.629041,"eighty":17.258612,"marketCap":3395768056},{"date":"2024-04-26","current":35.44199,"twenty":-10.056469,"median":-3.625758,"eighty":17.840762,"marketCap":3437873054},{"date":"2024-05-03","current":36.498796,"twenty":-10.056469,"median":-3.625758,"eighty":18.170174,"marketCap":3357889189},{"date":"2024-05-10","current":36.511207,"twenty":-10.056469,"median":-3.625758,"eighty":18.755351,"marketCap":3359031034},{"date":"2024-05-17","current":37.541304,"twenty":-10.056469,"median":-3.625758,"eighty":19.13678,"marketCap":3453799934},{"date":"2024-05-24","current":36.396752,"twenty":-10.056469,"median":-3.625758,"eighty":19.228198,"marketCap":3348501156},{"date":"2024-05-31","current":35.595565,"twenty":-10.056469,"median":-3.625758,"eighty":19.551549,"marketCap":3274792011},{"date":"2024-06-07","current":34.863052,"twenty":-10.056469,"median":-3.625758,"eighty":19.788169,"marketCap":3207400793},{"date":"2024-06-14","current":34.496795,"twenty":-10.059306,"median":-3.629041,"eighty":19.972394,"marketCap":3173705183},{"date":"2024-06-21","current":33.832955,"twenty":-10.062143,"median":-3.632324,"eighty":20.117746,"marketCap":3112631892},{"date":"2024-06-28","current":34.061866,"twenty":-10.071657,"median":-3.634664,"eighty":20.170141,"marketCap":3133691648},{"date":"2024-07-05","current":33.398026,"twenty":-10.071657,"median":-3.634664,"eighty":20.359437,"marketCap":3072618356},{"date":"2024-07-12","current":32.779968,"twenty":-10.071657,"median":-3.634664,"eighty":20.997672,"marketCap":3015757016},{"date":"2024-07-15","current":33.466699,"twenty":-10.071657,"median":-3.634664,"eighty":21.055774,"marketCap":3078936283},{"date":"2024-08-02","current":10.070358,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3081529526},{"date":"2024-08-09","current":9.455895,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2893503995},{"date":"2024-08-16","current":9.763127,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2987516760},{"date":"2024-08-23","current":10.179596,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3114956286},{"date":"2024-08-30","current":10.309316,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3154650565},{"date":"2024-09-06","current":9.742645,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2981249243},{"date":"2024-09-13","current":9.408104,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2878879787},{"date":"2024-09-20","current":10.718957,"twenty":-10.150883,"median":-3.673418,"eighty":21.101408,"marketCap":3280000919},{"date":"2024-09-27","current":10.084013,"twenty":-10.150883,"median":-3.673418,"eighty":20.560563,"marketCap":3085707871},{"date":"2024-10-04","current":9.585615,"twenty":-10.150883,"median":-3.673418,"eighty":20.205634,"marketCap":2933198274},{"date":"2024-10-11","current":9.756299,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2985427588},{"date":"2024-10-18","current":9.626579,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2945733309},{"date":"2024-10-25","current":9.462723,"twenty":-10.150883,"median":-3.673418,"eighty":20.138028,"marketCap":2895593168},{"date":"2024-10-31","current":8.714822,"twenty":-10.150883,"median":-3.673418,"eighty":19.647887,"marketCap":2902035670},{"date":"2024-11-08","current":9.117754,"twenty":-10.153746,"median":-3.674208,"eighty":19.166669,"marketCap":3036211945},{"date":"2024-11-15","current":9.111555,"twenty":-10.153746,"median":-3.674208,"eighty":18.78122,"marketCap":3034147899},{"date":"2024-11-22","current":9.099159,"twenty":-10.153746,"median":-3.674208,"eighty":16.930479,"marketCap":3030019806},{"date":"2024-11-29","current":9.638414,"twenty":-10.153746,"median":-3.674208,"eighty":16.766106,"marketCap":3209591825},{"date":"2024-12-06","current":9.756182,"twenty":-10.153746,"median":-3.674208,"eighty":16.574337,"marketCap":3248808703},{"date":"2024-12-13","current":9.53924,"twenty":-10.153746,"median":-3.674208,"eighty":16.377088,"marketCap":3176567086},{"date":"2024-12-20","current":8.968994,"twenty":-10.153746,"median":-3.674208,"eighty":16.1771,"marketCap":2986674836},{"date":"2024-12-27","current":9.334695,"twenty":-10.153746,"median":-3.674208,"eighty":15.960675,"marketCap":3108453562},{"date":"2025-01-03","current":8.541308,"twenty":-10.153746,"median":-3.674208,"eighty":15.74151,"marketCap":2844255649},{"date":"2025-01-10","current":8.398747,"twenty":-10.15661,"median":-3.674999,"eighty":15.187166,"marketCap":2796782587},{"date":"2025-01-17","current":8.429738,"twenty":-10.15661,"median":-3.674999,"eighty":14.123802,"marketCap":2807102818},{"date":"2025-01-24","current":8.541308,"twenty":-10.15661,"median":-3.674999,"eighty":12.229294,"marketCap":2844255649},{"date":"2025-01-31","current":8.355358,"twenty":-10.15661,"median":-3.674999,"eighty":11.774076,"marketCap":2782334264},{"date":"2025-02-07","current":8.175606,"twenty":-10.15661,"median":-3.674999,"eighty":11.669683,"marketCap":2722476924},{"date":"2025-02-14","current":7.915276,"twenty":-10.15661,"median":-3.674999,"eighty":11.541332,"marketCap":2635786984},{"date":"2025-02-21","current":12.449378,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2639268117},{"date":"2025-02-28","current":11.712888,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2483132177},{"date":"2025-03-07","current":11.32214,"twenty":-10.159473,"median":-3.675279,"eighty":11.440344,"marketCap":2400293756},{"date":"2025-03-14","current":10.388159,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2202289726},{"date":"2025-03-21","current":11.045758,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2341700727},{"date":"2025-03-28","current":10.62642,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2252800958},{"date":"2025-04-04","current":9.263569,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":1963876709},{"date":"2025-04-11","current":8.979147,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1903579170},{"date":"2025-04-17","current":9.09341,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1927802871},{"date":"2025-04-24","current":9.417154,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":1996436690}],"updateTime":1745574666983}}}